select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H2 2015

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H2 2015


  • Products Id :- GMDHC7252IDB
  • |
  • Pages: 199
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Review, H2 2015', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Overview 9

Therapeutics Development 10

Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Overview 10

Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Comparative Analysis 11

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Therapeutics under Development by Companies 12

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Products under Development by Companies 18

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Companies Involved in Therapeutics Development 21

Advaxis, Inc. 21

Amgen Inc. 22

AstraZeneca Plc 23

AVEO Pharmaceuticals, Inc. 24

Critical Outcome Technologies Inc. 25

Daiichi Sankyo Company, Limited 26

Genentech, Inc. 27

Glycotope GmbH 28

Immunovative Therapies, Ltd. 29

Laboratoires Pierre Fabre SA 30

Mabion SA 31

MedImmune, LLC 32

Merck & Co., Inc. 33

Novartis AG 34

Oncolytics Biotech Inc. 35

Ono Pharmaceutical Co., Ltd. 36

Panacea Biotec Limited 37

PCI Biotech AS 38

Shionogi & Co., Ltd. 39

Symphogen A/S 40

Threshold Pharmaceuticals, Inc. 41

VentiRx Pharmaceuticals, Inc. 42

Recurrent Head and Neck Cancer Squamous Cell Carcinoma-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Combination Products 44

Assessment by Target 45

Assessment by Mechanism of Action 47

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

AdIL-24-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AlloVax-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

alpelisib-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

axalimogene filolisbac-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

AZD-5069-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

AZD-9150-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

bleomycin sulfate-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

cetuximab biobetter-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

cetuximab biosimilar-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

cetuximab biosimilar-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

cetuximab biosimilar-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

COTI-2-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

duligotuzumab-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

durvalumab-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

durvalumab + tremelimumab-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

elgemtumab-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

ficlatuzumab-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

futuximab-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

motolimod-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

nivolumab-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

panitumumab-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

patritumab-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

pelareorep-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

pembrolizumab-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

S-488210-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

SB-01-Drug Profile 120

Product Description 120

Mechanism of Action 120

R&D Progress 120

tarloxotinib bromide-Drug Profile 122

Product Description 122

Mechanism of Action 122

R&D Progress 122

vinflunine ditartrate-Drug Profile 124

Product Description 124

Mechanism of Action 124

R&D Progress 124

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Recent Pipeline Updates 126

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects 194

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products 195

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Product Development Milestones 196

Featured News & Press Releases 196

Aug 27, 2015: Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin 196

Appendix 198

Methodology 198

Coverage 198

Secondary Research 198

Primary Research 198

Expert Panel Validation 198

Contact Us 198

Disclaimer 199

List of Tables

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015 10

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd...1) 19

Products under Development by Companies, H2 2015 (Contd...2) 20

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Advaxis, Inc., H2 2015 21

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Amgen Inc., H2 2015 22

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AstraZeneca Plc, H2 2015 23

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 24

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Critical Outcome Technologies Inc., H2 2015 25

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 26

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Genentech, Inc., H2 2015 27

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Glycotope GmbH, H2 2015 28

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Immunovative Therapies, Ltd., H2 2015 29

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Laboratoires Pierre Fabre SA, H2 2015 30

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Mabion SA, H2 2015 31

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by MedImmune, LLC, H2 2015 32

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Merck & Co., Inc., H2 2015 33

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Novartis AG, H2 2015 34

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Oncolytics Biotech Inc., H2 2015 35

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 36

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Panacea Biotec Limited, H2 2015 37

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by PCI Biotech AS, H2 2015 38

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Shionogi & Co., Ltd., H2 2015 39

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Symphogen A/S, H2 2015 40

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 41

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 42

Assessment by Monotherapy Products, H2 2015 43

Assessment by Combination Products, H2 2015 44

Number of Products by Stage and Target, H2 2015 46

Number of Products by Stage and Mechanism of Action, H2 2015 48

Number of Products by Stage and Route of Administration, H2 2015 50

Number of Products by Stage and Molecule Type, H2 2015 52

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics-Recent Pipeline Updates, H2 2015 126

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Dormant Projects, H2 2015 194

Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Discontinued Products, H2 2015 195

List of Figures

Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015 10

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 16

Assessment by Monotherapy Products, H2 2015 43

Number of Products by Top 10 Targets, H2 2015 45

Number of Products by Stage and Top 10 Targets, H2 2015 45

Number of Products by Top 10 Mechanism of Actions, H2 2015 47

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 47

Number of Products by Routes of Administration, H2 2015 49

Number of Products by Stage and Routes of Administration, H2 2015 49

Number of Products by Molecule Types, H2 2015 51

Number of Products by Stage and Molecule Types, H2 2015 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Amgen Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

Daiichi Sankyo Company, Limited

Genentech, Inc.

Glycotope GmbH

Immunovative Therapies, Ltd.

Laboratoires Pierre Fabre SA

Mabion SA

MedImmune, LLC

Merck & Co., Inc.

Novartis AG

Oncolytics Biotech Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Biotec Limited

PCI Biotech AS

Shionogi & Co., Ltd.

Symphogen A/S

Threshold Pharmaceuticals, Inc.

VentiRx Pharmaceuticals, Inc.

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutic Products under Development, Key Players in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Overview, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline, Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com